Group 1 - The core point of the article is that *ST Changyao has announced that as of the disclosure date, shareholder Shengshi Fenghua has had approximately 8.1 million shares frozen [2] - For the fiscal year 2024, *ST Changyao's revenue composition is as follows: 57.19% from the photovoltaic industry and 42.81% from the pharmaceutical industry [2]

证券代码：300391 证券简称：*ST长药 公告编号：2025-077 长江医药控股股份有限公司 关于控股股东部分股份冻结的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"、"长药控股"或"上市公 司"）近日接到控股股东长兴盛世丰华商务有限公司（以下简称"盛世丰华"） 的通知，盛世丰华持有的公司部分股份被冻结，具体事项如下： 一、股东股份被冻结的基本情况 | 股东 名称 | 是否为控股股东 或第一大股东及 | 本次冻结/标 记/拍卖等股 | 占其所持 | 占公司总 | 是否为限 售股及限 | | | 起始日 到期日 | | 冻结申请人 /拍卖人等 | 原因 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份比例 | 股本比例 | | | | | | | | | | 其一致行动人 | 份数量（股） | | | 售类型 | | | | | | | | 盛世 | 是 | 8,101,700 | 22 ...

证券代码：300391 证券简称：*ST长药 公告编号：2025-076 出席本次会议的有表决权的债权人共 202 家，占有表决权的债权人总数的 99.51%。 二、会议表决情况 长江医药控股股份有限公司 关于预重整第一次临时债权人会议和长江星等七家子公司 实质合并重整案第一次债权人会议召开及表决结果的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性陈述 或重大遗漏。 长江医药控股股份有限公司（以下简称"公司""长药控股"）于 2025 年 6 月 27 日在巨潮资讯网披露了《关于预重整第一次临时债权人会议和长江星等七家子公司实质 合并重整案第一次债权人会议提示性公告》，根据十堰市中级人民法院（以下简称"十 堰中院"）（2024）鄂 03 破申 76 号《公告》，十堰中院于 2025 年 7 月 15 日上午 9:30 通过网络方式（"小火鸟智慧破产平台"进行网络会议直播）召开长药控股预重整第一 次临时债权人会议。根据十堰中院（2025）鄂 03 破 1 号《公告》，十堰中院于 2025 年 7 月 15 日下午 14:30 通过网络方式（"小火鸟智慧破产平台"进行网络会议直 ...

Core Viewpoint - The company, Changjiang Pharmaceutical Holdings Co., Ltd., has entered a pre-restructuring phase as decided by the Shiyan Intermediate People's Court, which has appointed a temporary administrator for the restructuring process [1][2]. Summary by Sections Pre-restructuring Basic Situation - The Shiyan Intermediate People's Court has initiated pre-restructuring for the company and appointed Shanghai Jintiancheng Law Firm as the temporary administrator [1]. Progress Situation - The pre-restructuring period has been extended by three months until October 20, 2025 [2]. - A series of announcements regarding the restructuring process have been made, including the recruitment of investors and the status of subsidiary restructuring [2]. Creditors' Meeting - The first creditors' meeting was held on time, covering various agenda items including the temporary administrator's report and the verification of creditor claims [3]. - Creditors participated in the meeting through an online voting platform, with a voting deadline set for July 18, 2025 [3]. Financial Condition - As of December 31, 2024, the company's consolidated financial statements show a net asset value of -432.84 million yuan and a net profit of -627.96 million yuan for the year [5]. - The company has experienced a significant decline in revenue, dropping from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [5]. - The company is facing substantial overdue debts, with a total of 1.106 billion yuan in interest-bearing liabilities, and a high percentage of its bank accounts frozen [6][7]. Tax Obligations - The company’s subsidiary, Changjiang Star, has an outstanding tax obligation of 120 million yuan, which may affect its financial operations [7][8]. Information Disclosure - The company is committed to timely information disclosure regarding the restructuring process and has designated specific media outlets for announcements [8].

证券代码：300391 证券简称：*ST长药 公告编号： 2025-075 长江医药控股股份有限公司 关于预重整事项进展暨收到预重整延期批复的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、预重整基本情况 2025年1月20日，长江医药控股股份有限公司（以下简称"公司"或"长药控股" ）收到湖北省十堰市中级人民法院（下称"十堰中院"）送达的《决定书》，十堰 中院决定对公司启动预重整，并指定上海市锦天城律师事务所担任公司预重整期间 的临时管理人。具体内容详见公司于2025年1月21日在巨潮资讯网披露的《关于法 院同意公司启动预重整程序并指定预重整临时管理人的公告》。 根据进展情况，公司于2025年1月23日在巨潮资讯网披露了《关于公司预重整 案债权申报的公告》、《关于临时管理人公开招募和遴选投资人的公告》；2025 年2月13日披露了《关于公司子公司被债权人申请重整的提示性公告》；2025年3 月14日披露了《关于法院裁定受理子公司重整并指定重整管理人的公告》；2025 年4月2日披露了《关于预重整事项的进展公告》；2025年4月15日披露了《关于预 重 ...

Group 1 - The board of directors of Changjiang Pharmaceutical Holdings Co., Ltd. held its first meeting of the sixth session on July 14, 2025, via on-site and remote voting methods due to urgency [1] - All 9 participating directors voted in favor of the proposals, resulting in a unanimous approval with no votes against or abstentions [2] - The meeting's procedures and methods complied with relevant laws, regulations, and the company's articles of association [1][2] Group 2 - The board's resolutions included the completion of the board's re-election and the appointment of senior management and securities representatives [2] - The proposals were reviewed and approved by the company's board nomination committee prior to the meeting [2]

Meeting Details - The meeting was held on July 14, 2025, with a total of 129 shareholders (or their representatives) attending, holding 39,039,250 shares, which accounts for 11.1434% of the total shares [1] - The meeting included both on-site attendance and online voting, with 127 shareholders participating through online voting, representing 3,615,550 shares [1] Voting Results - The voting results for the proposals were conducted through both on-site and online methods, with specific proposals receiving more than two-thirds approval from the attending shareholders [2][3] - The proposals included amendments to the company's articles of association and other governance documents, which were previously approved in board meetings [5][6] Legal Opinion - Hubei Yingda Law Firm provided a legal opinion confirming that the meeting's convening, attendance, and voting procedures complied with relevant laws and regulations, deeming the resolutions valid [6]

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management and securities representatives at Changjiang Pharmaceutical Holdings Co., Ltd. [1] Group 1: Board of Directors - The sixth board of directors consists of 9 members, including 3 independent directors, with a term of three years starting from the date of election [1] - The board members meet the qualifications set by the Company Law of the People's Republic of China and other relevant regulations, with no history of penalties from the China Securities Regulatory Commission [1][2] - The independent directors have obtained the necessary qualifications, with one member committed to completing the required training [1] Group 2: Specialized Committees - The sixth board has established four specialized committees: Strategy Committee, Nomination Committee, Audit Committee, and Compensation and Assessment Committee [2] - The Audit Committee is chaired by Wei Jian, with members Du Shiming and Gao Yinghui [2] - The Nomination Committee is chaired by Sun Zhaohong, with members Du Shiming and Gu Ziguang [2] Group 3: Senior Management Appointments - The board has appointed senior management and securities representatives for a term of three years, starting from the first meeting of the sixth board [4] - The board secretary and securities representative have obtained the necessary qualifications from the Shenzhen Stock Exchange [5] - The appointed senior management members meet the qualifications required by the Company Law and have no disqualifying conditions [5] Group 4: Departures of Board Members - Yang Changsheng has stepped down from his position as an independent director and related committee roles, with no shares held in the company [6] - Three supervisors, Li Xian, Qin Ziyin, and Liu Tingting, have also left their positions, with no shares held and no unfulfilled commitments [6]

证券代码：300391 证券简称：*ST长药 编号：2025-072 1、召集人：公司董事会 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 2、召开方式：现场投票与网络投票相结合的方式 长江医药控股股份有限公司 2025年第三次临时股东会决议公告 一、会议召开和出席情况 3、召开时间： （1）现场会议时间：2025 年 7 月 14 日（星期一）下午 15:30 （2）网络投票时间：2025 年 7 月 14 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 7 月 14 日上午 9:15-9:25，9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 7 月 14 日 9:15-15:00。 4、股权登记日：2025 年 7 月 7 日（星期一） 5、现场会议召开地点：公司会议室（十堰市郧阳经济开发区天马大道特 69 号） 6、会议主持人：公司董事长王波先生。 7、会议出席 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2025-073 长江医药控股股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第六届董事会第一次会议 于2025年7月14日以现场加通讯表决方式召开。因情况紧急，会议通知于2025年7 月14日以电子邮件方式送达，会议召集人王波先生在会议上进行了说明。本次会 议由王波先生主持，应参与表决董事9人，实际参与表决董事9人，其中翁浩先 生、赵守军先生、高应会先生、顾紫光先生、韩庆凯先生以通讯方式出席并表 决。本次会议召集、召开的程序、方式符合有关法律、行政法规、部门规章、规 范性文件和公司章程规定。 二、董事会会议审议情况 1、关于选举公司第六届董事会董事长的议案 详情参见与本公告同日披露于巨潮资讯网的《关于董事会完成换届选举并聘 任高级管理人员、证券事务代表的公告》。 表决情况：赞成：9票；反对：0票；弃权：0票。 表决结果：通过。 表决结果：通过。 3、关于聘任公司总经理的议案 本议案已经公司 ...